WallStSmart

Mediwound Ltd (MDWD)vsMerck & Company Inc (MRK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 567868% more annual revenue ($67.38B vs $11.86M). MRK leads profitability with a 3.6% profit margin vs -170.1%. MRK earns a higher WallStSmart Score of 44/100 (D).

MDWD

Avoid

15

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 6.7Quality: 6.5
Piotroski: 4/9Altman Z: -3.32

MRK

Hold

44

out of 100

Grade: D

Growth: 3.3Profit: 6.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDWDUndervalued (+42.3%)

Margin of Safety

+42.3%

Fair Value

$29.88

Current Price

$13.39

$16.49 discount

UndervaluedFair: $29.88Overvalued
MRKSignificantly Overvalued (-76.6%)

Margin of Safety

-76.6%

Fair Value

$84.66

Current Price

$144.70

$60.04 premium

UndervaluedFair: $84.66Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDWD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.279/10

Conservative balance sheet, low leverage

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$368.89B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
41.2%10/10

Strong operational efficiency at 41.2%

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

MDWD4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$171.71M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-63.0%2/10

ROE of -63.0% — below average capital efficiency

Revenue GrowthGrowth
-45.8%2/10

Revenue declined 45.8%

MRK4 concerns · Avg: 3.5/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : MDWD

The strongest argument for MDWD centers on Debt/Equity.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : MDWD

The primary concerns for MDWD are EPS Growth, Market Cap, Return on Equity.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.

Key Dynamics to Monitor

MDWD profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

MRK carries more volatility with a beta of 0.22 — expect wider price swings.

MRK is growing revenue faster at 4.7% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (44/100 vs 15/100). MDWD offers better value entry with a 42.3% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Mediwound Ltd

HEALTHCARE · BIOTECHNOLOGY · USA

MediWound Ltd., a biopharmaceutical company, develops, manufactures and markets new and biotherapeutic solutions for tissue repair and regeneration. The company is headquartered in Yavne, Israel.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?